BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)
March 31 (Reuters) - Biomx Inc PHGE.A:
BIOMX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TRIAL EVALUATING BX211 FOR THE TREATMENT OF DIABETIC FOOT OSTEOMYELITIS (DFO)
BIOMX INC - BX211 FOUND TO BE SAFE AND WELL-TOLERATED
BIOMX INC -PLANNING FOR A PHASE 2/3 TRIAL OF BX211, PENDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) FEEDBACK
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
TSLA Q1 Earnings Preview: Tesla Snaps 8-Week Slump—Now Buy the Dip or Wait?

Why AMD Stock Popped: 12-Day Winning Rally Signals CPU Renaissance in Agentic AI Push

APLD Stock Surge: How CoreWeave Lease Amendments and Delta Forge 1 Milestones De-risk the Bull Case

AI Chip Startup Cerebras Refiles for IPO, Testing Nvidia’s Pricing Power

GPT-Rosalind Sparks CRO Sector Slump: Should Investors Buy the Dip or Exit Amid AI Drug R&D Impact?

Tradingkey








